Literature DB >> 20538456

Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.

Denis J Kertesz1, Christine Brotherton-Pleiss, Minmin Yang, Zhanguo Wang, Xianfeng Lin, Zongxing Qiu, Donald R Hirschfeld, Shelley Gleason, Taraneh Mirzadegan, Pete W Dunten, Seth F Harris, Armando G Villaseñor, Julie Qi Hang, Gabrielle M Heilek, Klaus Klumpp.   

Abstract

An analysis of the binding motifs of known HIV-1 non-nucleoside reverse transcriptase inhibitors has led to discovery of novel piperidine-linked aminopyrimidine derivatives with broad activity against wild-type as well as drug-resistant mutant viruses. Notably, the series retains potency against the K103N/Y181C and Y188L mutants, among others. Thus, the N-benzyl compound 5k has a particularly attractive profile. Synthesis and SAR are presented and discussed, as well as crystal structures relating to the binding motifs. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538456     DOI: 10.1016/j.bmcl.2010.05.040

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.

Authors:  Bryan D Cox; Anthony R Prosser; Yongnian Sun; Zhufang Li; Sangil Lee; Ming B Huang; Vincent C Bond; James P Snyder; Mark Krystal; Lawrence J Wilson; Dennis C Liotta
Journal:  ACS Med Chem Lett       Date:  2015-05-06       Impact factor: 4.345

2.  Computer-aided discovery of anti-HIV agents.

Authors:  William L Jorgensen
Journal:  Bioorg Med Chem       Date:  2016-07-21       Impact factor: 3.641

3.  Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.

Authors:  Tomoaki Sasaki; Zachary T K Gannam; Shalley N Kudalkar; Kathleen M Frey; Won-Gil Lee; Krasimir A Spasov; William L Jorgensen; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2019-06-26       Impact factor: 2.823

4.  Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design.

Authors:  Kathleen M Frey; Mariela Bollini; Andrea C Mislak; José A Cisneros; Ricardo Gallardo-Macias; William L Jorgensen; Karen S Anderson
Journal:  J Am Chem Soc       Date:  2012-11-19       Impact factor: 15.419

5.  One-pot synthesis of 2-amino-indole-3-carboxamide and analogous.

Authors:  Kan Wang; Eberhardt Herdtweck; Alexander Dömling
Journal:  ACS Comb Sci       Date:  2010-12-17       Impact factor: 3.784

6.  Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.

Authors:  Kathleen M Frey; William T Gray; Krasimir A Spasov; Mariela Bollini; Ricardo Gallardo-Macias; William L Jorgensen; Karen S Anderson
Journal:  Chem Biol Drug Des       Date:  2014-03-14       Impact factor: 2.817

7.  A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase.

Authors:  Andrea C Mislak; Kathleen M Frey; Mariela Bollini; William L Jorgensen; Karen S Anderson
Journal:  Biochim Biophys Acta       Date:  2014-04-12

8.  Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.

Authors:  Dongwei Kang; Xiao Ding; Gaochan Wu; Zhipeng Huo; Zhongxia Zhou; Tong Zhao; Da Feng; Zhao Wang; Ye Tian; Dirk Daelemans; Erik De Clercq; Christophe Pannecouque; Peng Zhan; Xinyong Liu
Journal:  ACS Med Chem Lett       Date:  2017-10-19       Impact factor: 4.345

9.  Identification of a novel sulfonamide non-nucleoside reverse transcriptase inhibitor by a phenotypic HIV-1 full replication assay.

Authors:  Tae-Hee Kim; Yoonae Ko; Thierry Christophe; Jonathan Cechetto; Junwon Kim; Kyoung-Ae Kim; Annette S Boese; Jean-Michel Garcia; Denis Fenistein; Moon Kyeong Ju; Junghwan Kim; Sung-Jun Han; Ho Jeong Kwon; Vincent Brondani; Peter Sommer
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.